What is MorphoSys AG (MPSYF)?

MorphoSys AG (MPSYF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of MPSYF?

The current price of MPSYF is $73.27. Prices are updated in real time on Stocks360.

What is MPSYF's price-to-earnings (PE) ratio?

MPSYF's trailing twelve-month PE ratio is -11.84, based on current price and earnings per share data available on Stocks360.

What is MPSYF's market capitalization?

MPSYF's market capitalization is $2,759,546,029.00, placing it in the mid-cap tier.

MorphoSys AG (MPSYF)

Stock analysis · OTC · Healthcare · Biotechnology

$73.27

Market Cap

$2.76B

PE (TTM)

-11.84

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.66

Day Range

$71.76 – $73.27

52-wk Range

$25.56 – $73.27

Avg Volume

N/A

Volume

100.00

MorphoSys AG (MPSYF) is a publicly traded company in the Healthcare sector. Latest price: $73.27. Market cap $2.76B. Trailing PE -11.84. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 8 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Aug 29, 2024

EPS $-2.26 vs est. $-1.33

Missed by $0.93

Proprietary Signals

Signal snapshot temporarily unavailable.

About MorphoSys AG

MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling cancer and autoimmune diseases. Among its key offerings is Tafasitamab, an antibody therapy approved for treating specific B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also boasts a robust pipeline, with several promising candidates under development. These include Pelabresib, a small molecule currently in Phase II clinical trials for myelofibrosis, and Felzartamab, a CD38-targeting antibody undergoing Phase I/II investigation for anti-PLA2R-positive membranous nephropathy, an autoimmune kidney disorder. Additionally, MorphoSys is developing CPI-0209, a small molecule in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. Beyond its proprietary projects, MorphoSys collaborates with pharmaceutical partners on other therapeutic programs. These include Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis, psoriatic arthritis, and palmoplantar pustulosi…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-11.84×
P/S (TTM)	10.35×
P/B	45.81×
PEG	0.24×
P/FCF (TTM)	-8.26×
EV / EBITDA	-41.74×
EV / Sales	12.35×
Earnings Yield	-8.44%
Free Cash Flow Yield	-12.11%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.94B
Revenue (TTM)	$238.28M
Net Income (TTM)	-$208.26M
Free Cash Flow (TTM)	-$187.01M
Net Debt	$477.43M
Working Capital	$549.71M
Gross Margin	75.51%
Operating Margin	-105.96%
Net Margin	-79.63%
Return on Equity	-183.80%
Return on Invested Capital	-13.30%